Nanomolar cationic dendrimeric sulfadiazine as potential antitoxoplasmic agent.

Abstract

The high doses of sulfadiazine (SDZ), used in synergistic combination with pyrimethamine, are mainly responsible for severe side effects and discontinuation of toxoplasmosis treatments. In the search for new strategies that improve the efficacy of treatments with reduced doses of SDZ, we have determined the performance of cationic G4 (DG4) and anionic G4.5… (More)

Topics

Cite this paper

@article{Prieto2006NanomolarCD, title={Nanomolar cationic dendrimeric sulfadiazine as potential antitoxoplasmic agent.}, author={Mar{\'i}a Jimena Prieto and Diana Bacigalupe and Oscar Ricardo Pardini and Javier Ignacio Amalvy and Cristina Venturini and Mar{\'i}a Jos{\'e} Morilla and Eder Lilia Romero}, journal={International journal of pharmaceutics}, year={2006}, volume={326 1-2}, pages={160-8} }